Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Treasury Shares (2023 - 2025)

Historic Treasury Shares for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Q3 2025 value amounting to $698019.0.

  • 4D Molecular Therapeutics' Treasury Shares rose 11237.88% to $698019.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $698019.0, marking a year-over-year increase of 11237.88%. This contributed to the annual value of $361997.0 for FY2024, which is 9979.85% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Treasury Shares is $698019.0, which was up 11237.88% from $725101.0 recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Treasury Shares ranged from a high of $748380.0 in Q1 2025 and a low of $181181.0 during Q4 2023
  • Its 3-year average for Treasury Shares is $438920.2, with a median of $345332.0 in 2024.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Treasury Shares skyrocketed by 9979.85% in 2024 and then skyrocketed by 25654.12% in 2025.
  • 4D Molecular Therapeutics' Treasury Shares (Quarter) stood at $181181.0 in 2023, then surged by 99.8% to $361997.0 in 2024, then skyrocketed by 92.82% to $698019.0 in 2025.
  • Its Treasury Shares was $698019.0 in Q3 2025, compared to $725101.0 in Q2 2025 and $748380.0 in Q1 2025.